When it comes to prostate MRI, experience matters. Discover why choosing an expert with a proven track record can make all the difference in accurate, reliable results. keep reading
Let’s face it, guys. We’re not getting any younger. In fact, society is getting older. The Population Reference Bureau tells us that in the U.S, the number of those age 65 and up is expected to nearly double from 52 million in 2018 to 95 million by 2060... keep reading
Does PSA screening reduce PCa mortality, or doesn’t it? We know that PSA is not specific for cancer, since many prostate conditions can cause a rise in PSA blood levels. We also know that an elevated PSA can lead to a conventional TRUS-guided biopsy, and that such biopsies can either miss prostate cancer or... keep reading
Artificial Intelligence is transforming prostate MRI interpretation, making it faster and more precise. See how this breakthrough technology is elevating prostate health diagnostics. keep reading
Understanding erectile dysfunction can lead to better health and confidence. Discover five key facts about ED and how you can take control for a happier, healthier life. keep reading
Overtreatment of low-risk prostate cancer can leave men with lasting side effects from unnecessary whole-gland treatment. Today, advances like multiparametric MRI, active surveillance, and focal therapy are offering safer, smarter alternatives that protect health and preserve quality of life. keep reading
Men are often told to “tough it out,” but prostate cancer tells a different story. High?risk disease is linked to higher rates of major depression and suicide over 10+ years—and emerging evidence shows preexisting depression may further worsen survival—underscoring the need for early, ongoing support. keep reading
A recent dialogue published in JAMA highlights emerging hope in the world of prostate cancer. From liquid biopsies to treat-resistant therapies and AI-powered diagnostics, this professional exchange underscores how science is steadily improving detection, care, and outcomes. keep reading
New tools like biomarker tests and 3T mpMRI are transforming how doctors evaluate a high PSA. Learn how these innovations reduce unnecessary prostate biopsies—saving patients from risk, stress, and costs—while delivering greater clarity in prostate cancer diagnosis. keep reading
On May 18, 2025 it was formally announced that former President Joe Biden had been diagnosed with prostate cancer that has spread to bone. Speaking for all of us at the Sperling Prostate Center, our hearts go out to President Biden and his family. How was he diagnosed? According to news reports... keep reading
Testosterone, or low T. No matter what you call it, it’s time to debunk the myth that testosterone therapy for men with low T increases prostate cancer risk. It all began over 80 years ago. “In 1941 Huggins and Hodges reported that marked reductions in T by castration or estrogen treatment caused metastatic [prostate cancer keep reading
Check out the name of this type of prostate imaging: microultrasonography. It’s a mouthful, and if you have trouble pronouncing it, you’re not alone. Let me break it down: Micro = very small. You may know words like micrometer or micromanage, same idea. Ultrasono = ultrasound. Graphy = graphics. Put it all together and it keep reading
Today’s multiparametric MRI (mpMRI) has revolutionized the prostate cancer (PCa) world. Thanks to its high resolution, 3-dimensional imaging done by a powerful 3 Tesla (3T) magnet, experienced radiologists are able to identify areas that are suspicious for clinically significant PCa (csPCa). This helps avoid unnecessary biopsies, but if a biopsy is indicated, the area can keep reading
How times and technology change! Take, for example, the shift from a tangible book like the Yellow Pages to a digital one. At one time, paper copies of the Yellow Pages business directory were delivered to virtually every household in America. This hefty local book was the ultimate resource for finding a business or service keep reading
Today’s multiparametric MRI (mpMRI) is better than ever. When a patient’s PSA blood test raises suspicion of prostate cancer (PCa), mpMRI determines if a targeted biopsy is needed. It does this by making significant lesions visible prior to an invasive biopsy. Significant means Gleason 3+4 or greater, also characterized as Grade Group 2 or greater. keep reading